‘World IP Day' celebrated at SITAM
Vizianagaram: The Department of Management Studies SITAM College organised a thought-provoking workshop to mark World Intellectual Property (IP) Day.
The theme for this year, 'IP and Music: Feel the Beat of IP,' celebrates the powerful synergy between creativity, innovation, and intellectual property rights in sustaining a dynamic and inclusive global music industry.
Dr Bhavya Manjeera Patruni, Scientist and Deputy Manager at the National Research Development Corporation (NRDC) shed light on the significance of IP rights, particularly copyrights, patents, and trademarks not only in the music domain but also in the broader context of start-ups and entrepreneurship.
She emphasised how IP management supports innovators in safeguarding their creations and facilitating successful commercialisation.
SITAM's Institution's Innovation Council (IIC) has been at the forefront of fostering innovation and IP awareness among students. Its active engagement with national organisations like NRDC ensures that theoretical learning is complemented by practical exposure to the real-world innovation ecosystem.
SITAM Director Dr Majji Sashibhushana Rao, Principal Dr DV Ramamurthy and others have participated in the programme.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
a day ago
- Business Standard
IEX shares crash 10% on market coupling buzz; what should investors do?
IEX share price today: Indian Energy Exchange (IEX) witnessed a sudden decline in its share price on Wednesday, June 11, 2025. IEX shares tumbled 10.2 per cent today, hitting an intraday low of ₹188.5 per share on the BSE amid heavy volumes. The sudden decline in IEX share price came amid a report that Power Minister Manohar Lal could apprise all the relevant stakeholders on market coupling and its associated benefits. A report by TV channel CNBC TV18 said that market coupling would happen through a broad bid, and not any internal bid. Business Standard could not independently verify the report. At 3:05 PM, IEX stock was trading 7.8 per cent lower at ₹193.2 per share, weighed by 3.17 million volumes on the BSE. By comparison, around 1.5 million shares, on average, changed hands on the counter over the past two weeks. Combined with the volumes on the National Stock Exchange (NSE), around 69.21 million shares have changed hands on both the exchanges so far in trade. In the derivatives market, put options for IEX scrip jumped three-fold the average. This was the stock's biggest one-day decline in 15 weeks. What is market coupling? Market coupling is a process through which buy and sell bids from all the three power exchanges -- IEX, Power Exchange India Limited (PXIL), and Hindustan Power Exchange Limited (HPX) -- will be aggregated to arrive at a single market clearing price (MCP). At present, each power exchange collects their own buy and sell bids to arrive at a MCP of its own. This leads to variation in the price of electricity on each exchange. Market coupling process, in the electricity markets, aims to unify power trading platforms to ensure efficiency, transparency, and price discovery across interconnected markets. At present, India is exploring market coupling through a central entity, likely Grid-India, to unify price discovery for the Day-Ahead Market (DAM) and other segments. How will market coupling affect IEX? While market coupling is beneficial from consumer point of view as it will encourage more competition and transparency in the electricity prices, while improving liquidity across exchanges to reduce price volatility. Investors, typically, sell IEX shares due to market coupling fears as the exchange has a dominant market share of around 90 per cent in the electricity market. A level playing field across exchanges would threaten the influence it has in the price discovery mechanism. That apart, any shift in volumes or trade preference from IEX to other power exchanges could adversely affect IEX's revenue due to lower fee income. IEX share price history Over the past one month, IEX share price has surged around 11 per cent on the BSE as against a 4 per cent rise in the benchmark Sensex index. From its 52-week low level of ₹151 per share, the stock is up 39 per cent. IEX stock analysis: should you buy or sell IEX shares? According to analysts at Reliance Securities, the recent uptrend in IEX stock had helped it breach the previous resistance line on the daily chart. The stock's 10-day moving average line is well above the 21-day moving average line, indicating a bullish trend. Further, the Relative Strength Index (RSI) is showing a strong upward movement, reaching 73.18. The level is still below the 'overbought' threshold of 80. "Investors may consider taking an entry position at the current market price (CMP), as the stock could provide an opportunity for further upside movement. The Risk to Reward Ratio is favorable at 1: 1.60," the brokerage said in a note on Wednesday. The brokerage suggests investors buy IEX stock at current levels with a stop loss of ₹186. Their two-month share price target on the stock is ₹224, followed by ₹251. Fundamentally, JM Financial Institutional Equities has initiated coverage on IEX stock with a 'Buy' rating and a share price target of ₹231 as it believes the risk-reward is not in the favour the regulators who wish to implement market coupling (MC) to centralise scheduling and dispatch of power and reduce costs. Meanwhile, demand for power, both energy and peak power, in India has grown at an unprecedented rate of 8.5 per cent during FY21-24 vs the historical average of 4.5-5.5 per cent. It is projected to grow at a CAGR of more than 6 per cent during FY24-32. Further, the share of renewables (solar, wind) in total generation has increased from 10 per cent in FY20 to 14 per cent in FY25, and it is likely to increase to 24 per cent/35 per cent by FY27/FY32. IEX's revenue, meanwhile, grew from ₹198.6 crore in FY17 to ₹537.3 crore in FY25, registering a CAGR of 13 per cent, broadly in line with the growth in the power exchange market, which expanded at a CAGR of 15 per cent from FY17-FY24. During the same period, the company's Ebitda increased from ₹143.5 crore in FY17 to ₹453.7 crore in FY25, with Ebitda margin improving from 72 per cent to 84 per cent. "With rising power demand and an increasing share of exchange-based transactions in the total electricity market, we expect the volume traded through the exchange to grow at a CAGR of 13 per cent during FY25-28. This is estimated to drive growth in revenue, and PAT at CAGRs of 16 per cent and 14 per cent, respectively, over the same period," JM Financial said.
Mint
04-06-2025
- Mint
IEX electricity trade volume rises 14 pc to 10,946 million units in May
New Delhi, Jun 4 (PTI) The Indian Energy Exchange (IEX) on Wednesday said it has logged over 14 per cent growth in electricity traded volume at 10,946 million units (MU) in May as compared to the year-ago period. IEX had achieved monthly electricity trade volume of 9,568 MU in May 2024, the company data showed. A total of 17.43 lakh Renewable Energy Certificates (RECs) were traded during the month, marking a 65 per cent year-on-year increase, an IEX statement said. Market clearing price in the Day Ahead Market was at ₹ 4.12/unit during May 2025, a decline of 22 per cent year-on-year. Market clearing price in the Real Time Market fell 28 per cent year-on-year at ₹ 3.43/unit last month. The Day-Ahead Market (DAM) achieved 3,510 MU volume last month as compared to 4,371 MU volume in May 2024, a decline of 20 per cent. The Real-Time Electricity Market (RTM) reported highest ever monthly traded volume in May 2025 when the volume increased to 4,770 MU from 3,352 MU a year ago, an increase of 42 per cent. Day Ahead Contingency and Term-Ahead Market (TAM), comprising contingency, daily & weekly and monthly contracts up to 3 months, traded 1,684 MU in May 2025 as compared to 1,221 MU a year ago. IEX Green Market, comprising the Green Day-Ahead and Green Term-Ahead Market segments, achieved 915 MU volume during the month under review as compared to 622 MU in May 2024. The weighted average price in Green Day-Ahead Market (G-DAM) for May 2025 was ₹ 3.59/unit.
News18
04-06-2025
- News18
‘Not A Regulatory Body': Indian Pharmacopoeia Clarifies It Only Sets Standards For Drugs, Doesn't Enforce Them
Last Updated: The clarification comes in the wake of increased global scrutiny of Indian-made drugs The Indian Pharmacopoeia Commission (IPC) has issued a clarification on its role amid growing concerns over impurities in medicines and the quality of drug manufacturing in India, News18 has learnt. In a notice issued by the apex authority titled 'Clarification on impurity limits published in the Indian Pharmacopoeia", it mentions that the IPC 'is in receipt of enquiries from various stakeholders…" and hence, it has been issuing the clarification. The IPC, which is responsible for setting the official quality standards for medicines in India, made it clear that while it defines the standards for impurities in drugs, it is not involved in approving or regulating new medicines. It said that responsibility lies with regulatory bodies like the CDSCO (Central Drugs Standard Control Organisation) and State Licensing Authorities. Both government departments, the Indian Pharmacopoeia Commission (IPC) and the apex regulatory agency, CDSCO, are headed by Dr Rajeev Singh Raghuvanshi. Impurities are small amounts of unwanted substances that may be present in a drug. While some impurities are acceptable within strict limits, their control is crucial to ensure the safety and effectiveness of medicines. The IPC sets impurity limits based on global standards and scientific data submitted by drug manufacturers. These limits are meant to serve as guidelines for making safe medicines, but final approval is always in the hands of the drug regulators. 'The IPC is an autonomous institution under the Ministry of Health & Family Welfare that is solely responsible for setting official drug standards… The IPC does not have any role in the regulatory review and approval of new drugs in India…the CDSCO and/or state licensing authorities are competent to take regulatory decisions." The clarification comes in the wake of increased global scrutiny of Indian-made drugs. Experts had raised questions about whether the IP includes adequate impurity limits for commonly used medicines. However, IPC, in the notice, has reiterated that it works in a consultative and advisory capacity, not as a regulator or certifying body. 'Impurities may be considered by the regulatory authority, provided it is supported with valid scientific justification and relevant data," it said. The notice, signed by Raghuvanshi, also pointed out that 'it is clarified that, in any case, the IPC does not have the mandate to approve or endorse impurity specifications…" Moreover, it added, 'the IPC, being a standard-setting organisation, is also not responsible to express opinion or recommendation in such regulatory matters." In fact, it has asked drug-makers and stakeholders 'to engage with the IPC by submitting scientific evidence to support monograph revisions, wherever required, to promote harmonisation with global standards". First Published: June 04, 2025, 10:26 IST
